|Titre :||HIV prevention, treatment, care and support for people who use stimulant drugs. Technical guide|
|Auteurs :||UNODCCP ; OMS / WHO ; UNAIDS = ONUSIDA|
|Type de document :||Rapport|
|Editeur :||New York : United Nations / Nations Unies, 2019|
|Autre Editeur :||Vienna : UNODC|
|Format :||76 p.|
|Discipline :||MAL (Maladies infectieuses / Infectious diseases)|
Thésaurus TOXIBASEVIH ; PREVENTION ; PRISE EN CHARGE ; USAGER ; STIMULANTS ; TRAITEMENT ; HEPATITE ; INTERVENTION ; REDUCTION DES RISQUES ; COCAINE ; AMPHETAMINES ; DROGUES DE SYNTHESE ; INFECTION ; FACTEUR DE RISQUE ; CHEMSEX
Since the beginning of the HIV epidemic, the focus on HIV prevention, treatment and care among people who use drugs has concentrated on the needs of people who inject drugs, and mainly on those who inject opioids. However, data show that there are HIV-related risks associated with the use of non-injecting stimulant drugs, as well as with the unsafe injection of such drugs, including cocaine, amphetamine-type stimulants (excluding MDMA), and stimulant new psychoactive substances. Use of stimulant drugs has also been associated with higher risk of HIV transmission through unsafe sexual behaviours in certain subsets of key populations.
To achieve SDG target 3.3 and the UNAIDS Fast-Track strategy for ending AIDS by 2030, it is crucial to address the needs of people who use stimulant drugs who are at risk of HIV, with specific attention to the intersections among key populations. Ending the AIDS epidemic is only achievable if we ensure that the right people access the right services, delivered in the right place at the right time, leaving no one behind.
The purpose of this publication is to provide guidance on implementing HIV, hepatitis C and hepatitis B programmes for people who use stimulant drugs and who are at risk of contracting these viruses.
|Domaine :||Drogues illicites / Illicit drugs|
|Sous-type de document :||Guide pratique / Manual|
|Refs biblio. :||168|